We note that that the 5‐year mortality after CHD in those who are CHIP+ and AgeAccelHG+ approaches 60%, similar to the mortality seen in patients with intermediate‐risk MDS (Greenberg et al., 2012). Here, STUB1 is linked to myelodysplastic syndrome.